There is still room for in-depth molecular investigations of mechanisms affecting canonical and non-canonical NF-κB signaling in ABC-DLBCL, which could give birth to new ideas for precision medicines. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.